Recommendation ID
NG161/1
Question

Risk of systemic anticancer treatment in people with cancer and COVID-19: Are patients with cancer and COVID-19 who are receiving/have recently received systemic anticancer treatment (SACT) (that is, within the 4 weeks preceding a diagnosis of COVID-19) at increased risk of severe COVID-19 illness or death?

Any explanatory notes
(if applicable)

It is recommended that this research should also consider:

  • if there are specific types of SACT carrying increased risk of poor outcomes from COVID-19
  • if there are specific types of cancer for which SACT may carry increased risk of poor outcomes from COVID-19
  • if there is a difference in any risk of poor outcomes from COVID-19 between people who have received SACT alone, radiotherapy alone, or both SACT and radiotherapy
  • if there is a difference in any risk of poor outcomes from COVID-19 between children and young people who have received SACT and adults who have received SACT

Source guidance details

Comes from guidance
COVID-19 rapid guideline: delivery of systemic anticancer treatments
Number
NG161
Date issued
March 2020

Other details

Is this a recommendation for the use of a technology only in the context of research? No  
Is it a recommendation that suggests collection of data or the establishment of a register?   No  
Last Reviewed 30/09/2021